

ASX RELEASE (ASX: MDR)

MedAdvisor's Board evolves to support US growth opportunity

Melbourne, Australia, 28 February, 2022 - Medtech company, MedAdvisor Limited (**MedAdvisor** or the **Company**) announces the following changes to its Board of Directors, effective immediately, to support the next phase of the Company's growth, centred on the substantial US market growth opportunity:

- Appointment of Ms Linda Jenkinson as Non-executive Director and Chair
- Retirement of Chris Ridd as Non-executive Director and Chair.

Key highlights:

- Having successfully acquired and integrated Adheris, with around 80% of revenues and earnings now sourced in the US, MedAdvisor's Board is evolving to better support the Company in executing on the substantial US market growth opportunity.
- Based in the US for the past 30 years, and spending equal time in the US and Australia / New Zealand, Linda Jenkinson is a highly experienced public and private company board director and a successful growth company CEO. Linda understands the Australian pharmacy market through her involvement as a Director with the Guild Group.
- Her experience positions her well to take on the Chair role and provide leadership and guidance to support MedAdvisor in its next phase of growth.
- Having been Chair of the Company through the acquisition and successful integration of Adheris, Chris Ridd is retiring as Chair and from the Board as part of its planned transition towards a more US-centric focus.

As a CEO of high growth businesses for over 20 years, Ms Jenkinson has built businesses spanning multiple countries and understands the US, Australian and New Zealand markets well. Having co-founded five companies, including Dispatch Management Services (NASDAQ:DMSC), Ms Jenkinson was the third woman to list a company on NASDAQ. Companies

that she has co-founded have offered services in more than 80 countries and employed ~8,500 employees.

Prior to her time as CEO of DMSC and Les Concierges which she ran for 17 years, Ms Jenkinson spent 11 years as a strategy consultant and advisor to Fortune 500 CEOs and boards as a partner with A.T. Kearney and earlier in her career at Price Waterhouse.

Ms Jenkinson currently serves as a non-executive director of the Eclipx Group Limited (ASX:ECX) and Harbour Asset Management Limited (NZ). She is Chair of Jaxsta Limited (ASX:JXT) and Guild Trustee Services Pty Limited.

Ms Jenkinson's appointment to the Board as MedAdvisor's US-based Chair is consistent with the Company's strategy to create a stronger presence in the US market, including the Board appointments of Lucas Merrow (Adheris and Eliza founder) in August 2021 and RaeAnn Grossman (Cotiviti Commercial Director) in February 2022.

Commenting on Ms Jenkinson's appointment to the Company's Board as Chair, current Chair Chris Ridd said, *"MedAdvisor has been strengthening the Board as we execute our growth strategy, expanding in existing markets and products, while also entering new markets. Being based in the United States, Linda will provide a unique 'on the ground' perspective as we continue to scale up our US business and invest in capability to deliver on the substantial opportunities available in the world's largest medicines market. In addition, her experience on major boards and ASX-listed boards, including as Chair, will ensure a seamless transition."*

Commenting on her appointment, Ms Jenkinson said, *"I'm delighted to be given the opportunity to join MedAdvisor's Board, and am privileged to take the Chair role. Together with Rob, Chris has helped steer the Company over the past two years, stabilise the tech platform and successfully acquire and integrate Adheris. I wish Chris all the very best for his future endeavours and look forward to his continued support as a shareholder. There's a lot more to be done now the foundations have been put in place, and I'm excited by the growth potential I see for the business. I look forward to working closely with MedAdvisor's other Directors and senior management and supporting the business to fulfill its tremendous potential."*

- ENDS -

This document has been authorised for release by Naomi Lawrie, Company Secretary.

For more information:

Company

Simon Glover
Chief Financial Officer
corporate@medadvisor.com.au
+61 3 9095 3036

Investors

Ronn Bechler
ronn.bechler@marketeye.com.au
+61 400 009 774

Media

Greer Quinn
greer@forwardcomm.com.au
+61 433 753 557

About MedAdvisor

MedAdvisor is a world-class medication management platform that empowers patients to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects patients to tools and education materials from their preferred pharmacy. MedAdvisor works with 25,000 pharmacies in the US to deliver programs to help patients take their medication safely and effectively. In Australia, MedAdvisor has connected over 2.4 million patients through more than 70% of Australian pharmacies. MedAdvisor has partnered with Cotiviti in the US, and is on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: mymedadvisor.com/investors